Stock Analysis on Net

Intuitive Surgical Inc. (NASDAQ:ISRG)

Analysis of Solvency Ratios 
Quarterly Data

Microsoft Excel

Solvency Ratios (Summary)

Intuitive Surgical Inc., solvency ratios (quarterly data)

Microsoft Excel
Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Debt Ratios
Debt to equity 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to capital 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial leverage 1.12 1.14 1.14 1.13 1.13 1.16 1.17 1.17 1.16 1.17 1.15 1.14 1.13 1.14 1.13 1.13 1.14 1.15 1.15 1.16 1.16

Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).


Financial Leverage Ratio Analysis
The financial leverage ratio exhibits a generally stable trend over the reported periods. Starting at 1.16 at the end of the first quarter of 2020, the ratio shows a slight downward movement into 2021, reaching a low of 1.13 around mid-2021. This indicates a modest decrease in reliance on debt relative to equity during this time.
Throughout late 2021 and into 2022, the ratio fluctuates narrowly between 1.13 and 1.17, suggesting consistent leverage levels without significant shifts in capital structure. The highest point observed is 1.17, occurring in both the final quarter of 2021 and the third quarter of 2023.
Moving into 2023 and 2024, the financial leverage ratio remains within a tight range, with a slight overall decline observed by the end of the reported periods, reaching 1.12 in the first quarter of 2025. This mild decrease may reflect gradual repayment of debt or increased equity capital, enhancing financial stability.
The absence of data for debt to equity, debt to capital, and debt to assets ratios limits a more comprehensive understanding of the debt structure; however, the financial leverage ratio alone suggests a conservative and stable approach to leveraging over the five-year horizon.
Overall, the company maintains a low and stable financial leverage ratio, indicating minimal dependency on debt financing and implying a moderately low financial risk profile over the periods analyzed.

Debt Ratios


Debt to Equity

Intuitive Surgical Inc., debt to equity calculation (quarterly data)

Microsoft Excel
Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in thousands)
Total debt
Total Intuitive Surgical, Inc. stockholders’ equity 17,106,400 16,433,700 15,583,300 14,708,300 13,962,600 13,307,600 12,539,000 11,879,100 11,217,700 11,041,900 11,515,400 12,023,000 12,102,300 11,901,100 11,410,900 10,837,500 10,153,500 9,731,500 9,257,800 8,740,500 8,506,700
Solvency Ratio
Debt to equity1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Benchmarks
Debt to Equity, Competitors2
Abbott Laboratories 0.27 0.30 0.38 0.38 0.38 0.38 0.41 0.45 0.46 0.46 0.46 0.46 0.48 0.50 0.53 0.55 0.55 0.57 0.59 0.64 0.60
CVS Health Corp. 0.84 0.88 0.87 0.89 0.87 0.81 0.83 0.88 0.82 0.74 0.74 0.73 0.76 0.75 0.79 0.81 0.87 0.93 0.97 1.05 1.10
Elevance Health Inc. 0.71 0.76 0.62 0.66 0.65 0.64 0.65 0.66 0.68 0.66 0.66 0.66 0.65 0.64 0.64 0.66 0.69 0.60 0.61 0.62 0.68
Medtronic PLC 0.58 0.50 0.49 0.49 0.49 0.47 0.55 0.51 0.44 0.46 0.48 0.49 0.50 0.51 0.60 0.60 0.57 0.49 0.49 0.51 0.52
UnitedHealth Group Inc. 0.86 0.83 0.83 0.84 0.85 0.70 0.75 0.80 0.87 0.74 0.65 0.71 0.65 0.64 0.67 0.70 0.70 0.66 0.67 0.72 0.91

Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q1 2025 Calculation
Debt to equity = Total debt ÷ Total Intuitive Surgical, Inc. stockholders’ equity
= 0 ÷ 17,106,400 = 0.00

2 Click competitor name to see calculations.


The equity position shows a consistent upward trend over the reported quarters, indicating a strengthening financial base. Beginning from approximately 8.51 billion US dollars, total stockholders’ equity grows steadily, reaching over 17.1 billion US dollars by the latest period. This suggests sustained value creation and reinvestment within the company.

There is an absence of data regarding total debt and the debt to equity ratio throughout the periods, which precludes analysis of the company’s leverage and solvency from this dataset. Without information on debt levels, it is not possible to assess the capital structure dynamics or the balance between debt and equity financing.

Overall, the clear pattern is a solid and continuous increase in equity, reflecting potentially strong profitability and/or capital contributions. The missing debt figures limit a comprehensive evaluation of financial risk and capital management strategies.


Debt to Capital

Intuitive Surgical Inc., debt to capital calculation (quarterly data)

Microsoft Excel
Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in thousands)
Total debt
Total Intuitive Surgical, Inc. stockholders’ equity 17,106,400 16,433,700 15,583,300 14,708,300 13,962,600 13,307,600 12,539,000 11,879,100 11,217,700 11,041,900 11,515,400 12,023,000 12,102,300 11,901,100 11,410,900 10,837,500 10,153,500 9,731,500 9,257,800 8,740,500 8,506,700
Total capital 17,106,400 16,433,700 15,583,300 14,708,300 13,962,600 13,307,600 12,539,000 11,879,100 11,217,700 11,041,900 11,515,400 12,023,000 12,102,300 11,901,100 11,410,900 10,837,500 10,153,500 9,731,500 9,257,800 8,740,500 8,506,700
Solvency Ratio
Debt to capital1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Benchmarks
Debt to Capital, Competitors2
Abbott Laboratories 0.21 0.23 0.27 0.27 0.27 0.28 0.29 0.31 0.31 0.31 0.32 0.31 0.33 0.34 0.35 0.35 0.35 0.36 0.37 0.39 0.38
CVS Health Corp. 0.46 0.47 0.47 0.47 0.46 0.45 0.45 0.47 0.45 0.42 0.42 0.42 0.43 0.43 0.44 0.45 0.47 0.48 0.49 0.51 0.52
Elevance Health Inc. 0.41 0.43 0.38 0.40 0.39 0.39 0.39 0.40 0.41 0.40 0.40 0.40 0.39 0.39 0.39 0.40 0.41 0.38 0.38 0.38 0.41
Medtronic PLC 0.37 0.33 0.33 0.33 0.33 0.32 0.35 0.34 0.31 0.31 0.32 0.33 0.34 0.34 0.37 0.37 0.36 0.33 0.33 0.34 0.34
UnitedHealth Group Inc. 0.46 0.45 0.45 0.46 0.46 0.41 0.43 0.44 0.46 0.43 0.39 0.41 0.39 0.39 0.40 0.41 0.41 0.40 0.40 0.42 0.48

Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q1 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= 0 ÷ 17,106,400 = 0.00

2 Click competitor name to see calculations.


Total capital
The total capital demonstrates a consistent upward trend from March 31, 2020, through March 31, 2025. Beginning at approximately 8.51 billion USD in early 2020, total capital steadily increases each quarter, reaching an estimated 17.11 billion USD by the end of the period. This growth indicates ongoing accumulation of financial resources or equity over time without any recorded interruptions or declines.
Total debt and Debt to capital ratio
There is no data provided for total debt nor for the debt to capital ratio across all reported periods. As a result, no direct analysis can be made regarding the company’s leverage or changes in financing structure related to debt during the reported timeframe.

Debt to Assets

Intuitive Surgical Inc., debt to assets calculation (quarterly data)

Microsoft Excel
Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in thousands)
Total debt
Total assets 19,220,400 18,743,200 17,743,400 16,649,900 15,828,000 15,441,500 14,712,700 13,903,300 13,053,200 12,974,000 13,260,800 13,705,200 13,678,400 13,555,000 12,934,600 12,297,000 11,540,400 11,168,900 10,617,500 10,103,600 9,891,100
Solvency Ratio
Debt to assets1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Benchmarks
Debt to Assets, Competitors2
Abbott Laboratories 0.16 0.17 0.20 0.20 0.20 0.20 0.22 0.23 0.23 0.23 0.23 0.23 0.23 0.24 0.25 0.25 0.25 0.26 0.27 0.29 0.27
CVS Health Corp. 0.25 0.26 0.26 0.26 0.26 0.25 0.25 0.26 0.24 0.23 0.23 0.24 0.24 0.24 0.25 0.26 0.27 0.28 0.29 0.30 0.31
Elevance Health Inc. 0.25 0.27 0.23 0.25 0.24 0.23 0.22 0.23 0.23 0.23 0.23 0.23 0.23 0.24 0.23 0.24 0.24 0.23 0.24 0.24 0.26
Medtronic PLC 0.31 0.28 0.28 0.28 0.28 0.27 0.30 0.29 0.26 0.27 0.27 0.28 0.28 0.28 0.31 0.31 0.31 0.27 0.28 0.28 0.29
UnitedHealth Group Inc. 0.26 0.26 0.26 0.26 0.26 0.23 0.22 0.23 0.25 0.23 0.20 0.22 0.21 0.22 0.22 0.23 0.23 0.22 0.23 0.24 0.27

Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q1 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= 0 ÷ 19,220,400 = 0.00

2 Click competitor name to see calculations.


The total assets demonstrate a persistent upward trend over the observed periods. Starting at approximately $9,891 million as of March 31, 2020, the asset base steadily increased throughout the quarters. By March 31, 2025, total assets reached approximately $19,220 million, effectively nearly doubling over the five-year span. This growth suggests continued expansion and investment in asset acquisition or development.

There is no available data for total debt or the debt to assets ratio across the examined periods. Consequently, an analysis of the company's leverage or financial risk in terms of debt utilization is not feasible. The absence of debt data may imply minimal or no debt recorded in these quarterly financials or that the information was not disclosed during the periods in question.

Overall, the key discernible pattern is a steady increase in total assets, indicating growth in resource holdings or company scale. Without debt information, it is not possible to evaluate the impact of liabilities on the asset base or assess the company's financial leverage.


Financial Leverage

Intuitive Surgical Inc., financial leverage calculation (quarterly data)

Microsoft Excel
Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in thousands)
Total assets 19,220,400 18,743,200 17,743,400 16,649,900 15,828,000 15,441,500 14,712,700 13,903,300 13,053,200 12,974,000 13,260,800 13,705,200 13,678,400 13,555,000 12,934,600 12,297,000 11,540,400 11,168,900 10,617,500 10,103,600 9,891,100
Total Intuitive Surgical, Inc. stockholders’ equity 17,106,400 16,433,700 15,583,300 14,708,300 13,962,600 13,307,600 12,539,000 11,879,100 11,217,700 11,041,900 11,515,400 12,023,000 12,102,300 11,901,100 11,410,900 10,837,500 10,153,500 9,731,500 9,257,800 8,740,500 8,506,700
Solvency Ratio
Financial leverage1 1.12 1.14 1.14 1.13 1.13 1.16 1.17 1.17 1.16 1.17 1.15 1.14 1.13 1.14 1.13 1.13 1.14 1.15 1.15 1.16 1.16
Benchmarks
Financial Leverage, Competitors2
Abbott Laboratories 1.67 1.71 1.87 1.86 1.87 1.90 1.92 1.97 1.99 2.03 2.04 2.03 2.09 2.10 2.14 2.17 2.17 2.21 2.20 2.25 2.21
CVS Health Corp. 3.32 3.35 3.37 3.37 3.38 3.27 3.38 3.44 3.35 3.21 3.27 3.06 3.15 3.10 3.16 3.16 3.24 3.32 3.38 3.46 3.54
Elevance Health Inc. 2.82 2.83 2.66 2.68 2.76 2.77 2.88 2.86 2.92 2.83 2.86 2.82 2.79 2.70 2.74 2.75 2.83 2.61 2.55 2.55 2.60
Medtronic PLC 1.87 1.79 1.75 1.75 1.77 1.77 1.83 1.80 1.71 1.73 1.75 1.76 1.78 1.81 1.92 1.91 1.87 1.79 1.79 1.80 1.81
UnitedHealth Group Inc. 3.26 3.22 3.17 3.20 3.28 3.08 3.34 3.40 3.49 3.16 3.26 3.16 3.04 2.96 3.03 3.05 3.09 3.01 2.93 3.03 3.32

Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q1 2025 Calculation
Financial leverage = Total assets ÷ Total Intuitive Surgical, Inc. stockholders’ equity
= 19,220,400 ÷ 17,106,400 = 1.12

2 Click competitor name to see calculations.


Total Assets

Total assets have displayed a generally consistent upward trend over the observed periods. Starting from approximately $9.89 billion at the end of March 2020, total assets increased steadily, reaching around $19.22 billion by the end of March 2025. This growth trajectory indicates a more than doubling of total assets within five years, suggesting sustained investment or accumulation of assets despite some slight fluctuations around late 2022.

Notably, there was a slight dip in total assets in the second half of 2022, where the value decreased from approximately $13.71 billion in mid-2022 to about $12.97 billion by the end of that year. Afterwards, the asset base resumed its growth path, accelerating in the latter part of the timeline up to 2025.

Total Stockholders’ Equity

The total stockholders’ equity also showed a clear upward trend, increasing consistently from around $8.51 billion in March 2020 to about $17.11 billion by March 2025. This represents roughly a doubling over five years, reflecting either retained earnings growth, repurchase or issuance of equity, or a combination of these factors.

There was a peak in equity around early 2022 at about $12.10 billion, followed by a decline through to the end of 2022, dipping to approximately $11.04 billion. However, equity then rebounded steadily from early 2023 to early 2025, suggesting recovery and strengthening of the company’s net worth after this temporary decline.

Financial Leverage

The financial leverage ratio remained relatively stable, fluctuating within a narrow band between 1.12 and 1.17 throughout the entire period. This consistency suggests a balanced use of debt relative to equity, signifying neither aggressive leveraging nor significant deleveraging.

Specifically, the ratio slightly decreased from around 1.16 in early 2020 to as low as 1.12 toward the end of the observed period in March 2025. Such a trend implies a marginally reduced reliance on debt financing in relation to equity over time, which may indicate a conservative capital structure strategy or improved equity base growth outpacing debt accumulation.

Overall Insights

The steady growth in total assets coupled with the doubling of stockholders’ equity indicates a solid expansion of the company’s size and financial base. The temporary decreases observed around late 2022 for both assets and equity may point to specific operational or market challenges during that period; however, the subsequent recovery underscores resilience.

The stable financial leverage ratio throughout the period, remaining close to 1.15, suggests disciplined financial management with no significant shifts in debt levels relative to equity. This stability can be associated with manageable financial risk and consistent capital structure policies.